Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

The Journal of investigative dermatology - 1 Feb 2016

Vu Ha Linh, Rosenbaum Sheera, Capparelli Claudia, Purwin Timothy J, Davies Michael A, Berger Adam C, Aplin Andrew E

Abstract excerpt

Activating mutations in neuroblastoma RAS viral oncogene homolog (NRAS) are frequent driver events in cutaneous melanoma. NRAS is a guanosine triphosphate-binding protein whose most well-characterized downstream effector is RAF, leading to activation of mitogen-activated protein kinase (MEK)-extracellular signal-regulated protein kinase 1/2 signaling. Although there are no Food and Drug Administration-approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adaptor Proteins, Signal Transducing
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epidermal Growth Factor

Share to GTP Phosphohydrolases

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Skin Neoplasms

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26967478
DOI: 10.1016/j.jid.2015.11.012
PMCID: PMC4789776

Genes

NRAS
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.PMID 26967478Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.Semantic proximity Read ↗

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

MEK inhibitors for the treatment of NRAS mutant melanoma.Semantic proximity Read ↗

Treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

Diacylglycerol Kinase Eta as a Novel Target in NRAS Mutant Melanoma.Semantic proximity Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.